JPH06504195A - 鶏貧血症ウィルス(cav)組換え核酸、それを含むcav診断キット、および原核細胞または真核細胞、ならびにcav2本鎖dnaの製造方法 - Google Patents
鶏貧血症ウィルス(cav)組換え核酸、それを含むcav診断キット、および原核細胞または真核細胞、ならびにcav2本鎖dnaの製造方法Info
- Publication number
- JPH06504195A JPH06504195A JP3517451A JP51745191A JPH06504195A JP H06504195 A JPH06504195 A JP H06504195A JP 3517451 A JP3517451 A JP 3517451A JP 51745191 A JP51745191 A JP 51745191A JP H06504195 A JPH06504195 A JP H06504195A
- Authority
- JP
- Japan
- Prior art keywords
- cav
- dna
- protein
- gene
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000725585 Chicken anemia virus Species 0.000 title claims description 231
- 108020004414 DNA Proteins 0.000 title claims description 170
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 210000003527 eukaryotic cell Anatomy 0.000 title claims description 5
- 210000001236 prokaryotic cell Anatomy 0.000 title claims description 5
- 102000053602 DNA Human genes 0.000 title description 19
- 102000039446 nucleic acids Human genes 0.000 title description 5
- 108020004707 nucleic acids Proteins 0.000 title description 5
- 150000007523 nucleic acids Chemical class 0.000 title description 5
- 238000009007 Diagnostic Kit Methods 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims description 145
- 102000004169 proteins and genes Human genes 0.000 claims description 98
- 210000004027 cell Anatomy 0.000 claims description 94
- 238000000034 method Methods 0.000 claims description 77
- 241000700605 Viruses Species 0.000 claims description 41
- 239000002773 nucleotide Substances 0.000 claims description 36
- 125000003729 nucleotide group Chemical group 0.000 claims description 35
- 230000002068 genetic effect Effects 0.000 claims description 30
- 101150061458 cav gene Proteins 0.000 claims description 27
- 208000015181 infectious disease Diseases 0.000 claims description 23
- 239000013598 vector Substances 0.000 claims description 21
- 229960005486 vaccine Drugs 0.000 claims description 18
- 238000003752 polymerase chain reaction Methods 0.000 claims description 16
- 230000003053 immunization Effects 0.000 claims description 15
- 238000002649 immunization Methods 0.000 claims description 15
- 239000000975 dye Substances 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 238000002255 vaccination Methods 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 230000036039 immunity Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 230000001900 immune effect Effects 0.000 claims description 8
- 238000002955 isolation Methods 0.000 claims description 8
- 230000006798 recombination Effects 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 238000005215 recombination Methods 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 238000002105 Southern blotting Methods 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 229940031626 subunit vaccine Drugs 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 4
- 238000013507 mapping Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 241000271566 Aves Species 0.000 claims description 3
- 238000000636 Northern blotting Methods 0.000 claims description 3
- 239000013599 cloning vector Substances 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 206010020843 Hyperthermia Diseases 0.000 claims 1
- 238000000802 evaporation-induced self-assembly Methods 0.000 claims 1
- 230000004077 genetic alteration Effects 0.000 claims 1
- 231100000118 genetic alteration Toxicity 0.000 claims 1
- 230000036031 hyperthermia Effects 0.000 claims 1
- 230000000984 immunochemical effect Effects 0.000 claims 1
- 108020001775 protein parts Proteins 0.000 claims 1
- 230000008707 rearrangement Effects 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 229960004854 viral vaccine Drugs 0.000 claims 1
- 210000004885 white matter Anatomy 0.000 claims 1
- 238000004458 analytical method Methods 0.000 description 24
- 241000287828 Gallus gallus Species 0.000 description 20
- 235000013330 chicken meat Nutrition 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 108091008146 restriction endonucleases Proteins 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 15
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000000120 cytopathologic effect Effects 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 208000007502 anemia Diseases 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- 239000003298 DNA probe Substances 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000006758 Marek Disease Diseases 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 230000008774 maternal effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 238000009585 enzyme analysis Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 239000003104 tissue culture media Substances 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 241001516406 Avian orthoreovirus Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101150103768 CAM gene Proteins 0.000 description 2
- 101150104494 CAV1 gene Proteins 0.000 description 2
- 108020004638 Circular DNA Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 210000000078 claw Anatomy 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 244000144992 flock Species 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- QPUKANZXOGADOB-UHFFFAOYSA-N n-dodecyl-n-methylnitrous amide Chemical compound CCCCCCCCCCCCN(C)N=O QPUKANZXOGADOB-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- DGMKFQYCZXERLX-UHFFFAOYSA-N proglumide Chemical compound CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=CC=C1 DGMKFQYCZXERLX-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108091006091 regulatory enzymes Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- IXQPRUQVJIJUEB-UHFFFAOYSA-N 7-(diethylamino)-n-[2-(2,5-dioxopyrrol-1-yl)ethyl]-2-oxochromene-3-carboxamide Chemical compound O=C1OC2=CC(N(CC)CC)=CC=C2C=C1C(=O)NCCN1C(=O)C=CC1=O IXQPRUQVJIJUEB-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241000714230 Avian leukemia virus Species 0.000 description 1
- 101000688206 Bos taurus Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101000583080 Bunodosoma granuliferum Delta-actitoxin-Bgr2a Proteins 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 101100440696 Caenorhabditis elegans cor-1 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 101150047856 Cav2 gene Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 102100034114 DnaJ homolog subfamily C member 14 Human genes 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000701796 Fowl aviadenovirus 1 Species 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 101000870166 Homo sapiens DnaJ homolog subfamily C member 14 Proteins 0.000 description 1
- 241001580033 Imma Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000702626 Infectious bursal disease virus Species 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 101000882917 Penaeus paulensis Hemolymph clottable protein Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000003323 beak Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004367 thymic lymphocyte Anatomy 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10041—Use of virus, viral particle or viral elements as a vector
- C12N2750/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1、鶏貧血症ウィルス(CAV)遺伝子またはその一部のヌクレオチド配列に応 答し、またはそれを補充するCAV特異性ヌクレオチド配列からなる差別化され または差別化されないDNAまたはRNAの個体中での組替え遺伝子情報。 2、前記CAV遺伝子またはその一部のヌクレオチド配列が、図1で示される均 一なヌクレオチド配列を少なくとも60%含むことを特徴とする請求項1記載の 組替え遺伝子情報。 3、前記CAV遺伝子またはその一部のヌクレオチド配列が、CAV遺伝子中で 生じるCAV蛋白質のためにコード化するヌクレオチド配列かその一部であるこ とを特徴とする請求項1または請求項2記載の組替え遺伝子情報。 4、前記CAV遺伝子またはその一部のヌクレオチド配列が、CAV遺伝子中で 生じる制御因子を有するヌクレオチド配列かその一部であることを特徴とする請 求項1または請求項2記載の組替え遺伝子情報。 5、ヌクレオチド配列がCAV遺伝子から誘導されないことを特徴とする請求項 1〜請求項4のいずれか1項に記載の組替え遺伝子情報。 6、前記CAV遺伝子から誘導されないヌクレオチド配列が、真核生物または原 核生物において発現するベクターから誘導されたヌクレオチド配列であることを 特徴とする請求項5記載の組替え遺伝子情報。 7、前記CAV遺伝子から誘導されないヌクレオチド配列が、CAV蛋白質以外 の蛋白質のためにコード化するヌクレオチド配列または同様の他の蛋白質の一部 のためにコード化するヌクレオチド配列であることを特徴とする請求項5記載の 組替え遺伝子情報。 8、前記CAV遺伝子から誘導されないヌクレオチド配列が、CAV遺伝子中で 生じることがなく、制御因子を有するヌクレオチド配列であることを特徴とする 請求項5記載の組替え遺伝子情報。 9、前記DNAまたはRNA個体が、DNA個体であることを特徴とする請求項 1〜請求項8のいずれか1項に記載の組替え遺伝子情報。 10、前記DNAが放射性同位元素、酸素分子、ハブテン、蛍光物質、染料色素 および特殊な標識物のようなDNAの差別化に適した標識物で差別化されたDN Aであることを特徴とする請求項9記載の組替え遺伝子情報。 11、前記DNAまたはRNA個体が、RNA個体であることを特徴とする請求 項1〜請求項8のいずれか1項に記載の組替え遺伝子情報。 12、前記RNAが放射性同位元素、酵素分子、ハブテン、蛍光物質、染料、色 素および特殊な標識物のようなRNAの差別化に適した標識物で差別化されたR NAであることを特徴とする請求項9記載の組替え遺伝子情報。 13、DNAまたはRNA個体中でさらに組替えウィルス粒子に包囲されたこと を特徴とする請求項1〜請求項12のいずれか1項に記載の組替え遺伝子情報。 14、請求項1〜請求項13のいずれか1項に記載の組替え遺伝子情報を診断、 免疫化もしくは予防接種の目的またはCAV蛋白質もしくは非CAV蛋白質の生 産のために使用する方法。 15、CAV−DNAまたはCAV−RNAを検出する方法、たとえばDNA/ RNAスロットブロッティング、サザンブロッティング、ノーザンブロッティグ 、特定部位における組替え、ポリメラーゼ連鎖反応(PCR)によるDNA拡張 、S1マッピング、アライマエクステンションの方法におけるCAV特殊プロー ブまたはプライマとして請求項1〜請求項12のいずれか1項記載の組替え遺伝 子情報を使用する方法。 16、DNA/RNAスロットブロッティング、サザンブロッティング、ノーザ ンブロッティング、特定部位における組替え、PCRによるDNA拡張、S1マ ッピングのようなCAV−DNAまたはCAV−RNA検出のための診断器具に おいてCAV特殊プローブまたはプライマとして請求項1〜請求項12のいずれ か1項に記載の組替え遺伝子情報を用いることを特徴とする診断器具。 17、CAVまたは他の病原体に対する予防を実現するための生きたウィルスワ クチンとして請求項13に記載の組替え遺伝子情報を使用する方法。 18、CAVまたは他の病原体に対する免疫化のためのワクチン調合法において 、請求項1〜請求項13のいずれか1項に記載の組替え遺伝子情報および生きた ウィルスワクチンのために適する1つまたはそれ以上の抗体または補助物からな ることを特徴とするワクチン調合法。 19、CAV蛋白質、CAV蛋白以外の蛋白を試験中または生体中で製造するた めの方法において請求項1〜請求項13のいずれか1項に記載する組替え遺伝子 情報を使用する方法。 20、鳥類のクローニングベクターとして請求項1〜請求項13のいずれか1項 に記載の組替え遺伝子情報を使用する方法。 21、請求項1〜請求項13のいずれか1項に記載の組替え遺伝子情報を含むこ とを特徴とする無核または有核細胞。 22、請求項1〜請求項13のいずれか1項に記載の組替え遺伝子情報を含み、 前記遺伝子紺替え情報によってエンコードされた少なくとも1つの蛋白質または 蛋白質の部分の実現を可能にすることを特徴とする無核または有核細胞。 23、請求項1〜請求項13のいずれか1項に記載の組替え遺伝子情報が試験管 内の転位によって得られ、CAV蛋白質またはそ一部のためにコード化するヌク レオチド配列からなることを特徴とするCAV蛋白質またはその一部。 24、請求項1〜請求項13のいずれか1項に記載の組替え遺伝子情報を含み、 CAV蛋白質またはその一部のためにコード化するヌクレオチド配列からなり、 その実現を可能にする原核生物または真核生物の細胞から単離によって得られる ことを特徴とするCAV蛋白質またはその一部。 25、診断、免疫化もしくは予防接種の目的、またはCAV特殊抗体の製造のた めに請求項23または請求項24のいずれか1項記載のCAV蛋白質またはその 一部を使用する方法。 26、CAV特殊抗体を検出するための免疫的方法、たとえば免疫性過酸化酵素 、染料、EしISA、免疫性蛍光染料を用いる方法において、CAV特殊抗体を 結合する試薬として請求項23または請求項24のいずれか1項記載のCAV蛋 白質またはその一部を使用する方法。 27、免疫性過酸化酸素、染料、ELISAまたは、免疫性蛍光染料のような免 疫的方法を用いて、CAV特殊抗体を検出するための診断器具において、CAV 特殊抗体を結合する試薬として請求項23または請求項24のいずれか1項記載 のCAV蛋白質またはその一部を含むことを特徴とする診断器具。 28、CAVに対する防護を実現するためのサブユニットワクチンとして請求項 23または請求項24のいずれか1項記載のCAV蛋白質またはその一部を使用 する方法。 29、CAVに対する免疫を有するワクチン調整法において、請求項23または 請求項24のいずれか1項記載のCAV蛋白質またはその一部とサブユニットワ クチンのために適する任意の1つまたはそれ以上の抗体と補助体とからなること を特徴とする調整法。 30、CAV特殊ポリクロナールまたはモノクロナール抗体を調造するための過 程で請求項23または請求項24のいずれか1項記載のCAV蛋白質またはその 一部を使用する方法。 31、請求項23または請求項24のいずれか1項記載のCAV蛋白質またはそ の一部によって製造されたCAV特殊抗体。 32、診断、免疫もしくは予防接種の目的または調整法の目的のために請求項3 1に記載のCAV特殊抗体を使用する方法。 33、CAV蛋白質を検出する免疫的方法において試薬を結合するCAV蛋白質 として請求項31に記載のCAV特殊抗体を使用する方法。 34、免疫的方法でCAV蛋白質を検出するための診断器具において、試薬を結 合するCAV蛋白質として請求項30に記載のCAV特殊抗体を含むことを特徴 とする診断器具。 35、CAV感染に対する受動免疫のために請求項31に記載のCAV特殊抗体 を使用する方法。 36、CAVに対する受動免疫調整法において、請求項31のCAV特殊抗体と の任意の1つまたはそれ以上の受動免疫に適した抗体または補助体とからなるこ とを特徴とする調整法。 37、CAV蛋白質の単離および/または精製のための方法で請求項31に記載 の特殊抗体を使用する方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL9002008 | 1990-09-12 | ||
NL9002008A NL9002008A (nl) | 1990-09-12 | 1990-09-12 | Recombinant dna en rna en daarvan afgeleide produkten. |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06504195A true JPH06504195A (ja) | 1994-05-19 |
JP2846116B2 JP2846116B2 (ja) | 1999-01-13 |
Family
ID=19857669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3517451A Expired - Fee Related JP2846116B2 (ja) | 1990-09-12 | 1991-09-11 | 鶏貧血症ウィルス(cav)組換え核酸、それを含むcav診断キット、および原核細胞または真核細胞、ならびにcav2本鎖dnaの製造方法 |
Country Status (21)
Country | Link |
---|---|
US (6) | US5491073A (ja) |
EP (2) | EP0905246A1 (ja) |
JP (1) | JP2846116B2 (ja) |
AT (1) | ATE188739T1 (ja) |
AU (1) | AU651999B2 (ja) |
CA (1) | CA2091181C (ja) |
DE (1) | DE69131903T2 (ja) |
DK (1) | DK0548234T3 (ja) |
ES (1) | ES2144399T3 (ja) |
GR (1) | GR3033173T3 (ja) |
HR (1) | HRP940668B1 (ja) |
HU (1) | HU220102B (ja) |
IL (1) | IL99435A (ja) |
MX (1) | MX9101042A (ja) |
NL (1) | NL9002008A (ja) |
RU (1) | RU2146292C1 (ja) |
SI (1) | SI9111508B (ja) |
UA (1) | UA48936C2 (ja) |
WO (1) | WO1992004446A1 (ja) |
YU (1) | YU49095B (ja) |
ZA (1) | ZA917065B (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5922600A (en) * | 1990-09-12 | 1999-07-13 | Leadd Bv | Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1 VP2 and VP3 or sequences of that virus coding therefor |
US20020061296A1 (en) * | 2000-09-08 | 2002-05-23 | Noteborn Mathieu H.M. | Delivery method for the tumor specific apoptosis inducing activity of apoptin |
US20080234466A1 (en) * | 1990-09-12 | 2008-09-25 | Noteborn Mathieu H M | Delivery method for the tumor-specific apoptosis-inducing activity of apoptin |
NL9301272A (nl) * | 1993-07-20 | 1995-02-16 | Aesculaap Bv | Chicken Anemia Virus mutanten en vaccins en toepassingen gebaseerd op de virale eiwitten VP1, VP2 en VP3 of daarvoor coderende sequenties van dat virus. |
US20030138443A1 (en) * | 1993-03-08 | 2003-07-24 | Noteborn Mathews H.M. | Cloning of chicken anemia virus DNA |
ZA918426B (en) * | 1990-10-31 | 1992-12-30 | Akzo Nv | Chicken anemia virus vaccine and diagnostic |
EP0878546A1 (en) * | 1997-04-15 | 1998-11-18 | Leadd B.V. | A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin |
US5789567A (en) * | 1994-07-06 | 1998-08-04 | Cornell Research Foundation, Inc. | Chicken infectious anemia virus vaccine |
GB9414888D0 (en) * | 1994-07-23 | 1994-09-14 | Univ Belfast | Method and composition |
NZ309172A (en) * | 1995-06-07 | 1999-11-29 | Leadd B | Neutralizing conformational epitopes of chicken anemia virus |
AU1075197A (en) * | 1995-11-14 | 1997-06-05 | Mark A. Goodwin | Efficient method of detecting an infectious agent in blood |
PL196605B1 (pl) | 1997-08-12 | 2008-01-31 | Leadd Bv | Sposób oznaczania zdolności transformującej, sposób oznaczania predyspozycji do przekształcania się w komórkę nowotworową, sposób oznaczania predyspozycji do dziedziczenia rodzajów raka, sposób oznaczania mutacji genu i diagnostyczny zestaw testowy |
WO1999045956A1 (en) * | 1998-03-13 | 1999-09-16 | University Of Georgia Research Foundation, Inc. | Vaccines against circovirus infections |
ATE347597T1 (de) * | 1999-09-02 | 2006-12-15 | Leadd Bv | Apoptin bindendes protein |
JP2003516152A (ja) * | 1999-12-10 | 2003-05-13 | レアト ベー.フェー. | アポプチン会合タンパク質 |
US6593134B1 (en) | 2000-03-10 | 2003-07-15 | Cornell Research Foundation, Inc. | Method of propagating chicken infectious anemia virus |
DE60133495T2 (de) * | 2000-07-10 | 2009-07-09 | Uni-Charm Corp., Shikokuchuo | Reinigungsartikel |
EP1199363A1 (en) * | 2000-10-20 | 2002-04-24 | Leadd B.V. | Phosphorylation modifications of apoptin |
US20050169939A1 (en) * | 2001-09-05 | 2005-08-04 | Leonard Joan D. | Chicken anemia virus vaccine from cell line |
US7566548B2 (en) * | 2004-08-13 | 2009-07-28 | University Of Massachusetts | Methods for identifying therapeutic agents and for treating disease |
CN102636646A (zh) * | 2012-05-15 | 2012-08-15 | 扬州大学 | 快速检测禽白血病抗原的试纸条及其制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2042888B (en) | 1979-03-05 | 1983-09-28 | Teijin Ltd | Preparation for administration to the mucosa of the oral or nasal cavity |
JPS6034925B2 (ja) | 1979-07-31 | 1985-08-12 | 帝人株式会社 | 持続性鼻腔用製剤およびその製造法 |
JPS6032714A (ja) | 1983-08-01 | 1985-02-19 | Teijin Ltd | 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物 |
DE3583799D1 (de) | 1985-01-11 | 1991-09-19 | Abbott Lab Ltd | Feste zubereitung mit langsamer freisetzung. |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5059587A (en) | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
GB8723846D0 (en) | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
US5079005A (en) | 1988-06-17 | 1992-01-07 | Gupta Kashmiri L | Time release protein |
EP0748631B1 (en) * | 1988-09-13 | 2006-02-08 | Mérial | Viral vaccines |
GB2237510B (en) | 1989-11-04 | 1993-09-15 | Danbiosyst Uk | Small particle drug compositions for nasal administration |
US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
ZA918426B (en) | 1990-10-31 | 1992-12-30 | Akzo Nv | Chicken anemia virus vaccine and diagnostic |
-
1990
- 1990-09-12 NL NL9002008A patent/NL9002008A/nl not_active Application Discontinuation
-
1991
- 1991-09-05 ZA ZA917065A patent/ZA917065B/xx unknown
- 1991-09-06 IL IL99435A patent/IL99435A/en not_active IP Right Cessation
- 1991-09-11 US US08/030,335 patent/US5491073A/en not_active Expired - Lifetime
- 1991-09-11 JP JP3517451A patent/JP2846116B2/ja not_active Expired - Fee Related
- 1991-09-11 AU AU86580/91A patent/AU651999B2/en not_active Ceased
- 1991-09-11 CA CA002091181A patent/CA2091181C/en not_active Expired - Lifetime
- 1991-09-11 ES ES91917088T patent/ES2144399T3/es not_active Expired - Lifetime
- 1991-09-11 HU HU9300716A patent/HU220102B/hu not_active IP Right Cessation
- 1991-09-11 WO PCT/NL1991/000165 patent/WO1992004446A1/en active IP Right Grant
- 1991-09-11 RU RU93005170A patent/RU2146292C1/ru not_active IP Right Cessation
- 1991-09-11 EP EP98202968A patent/EP0905246A1/en not_active Withdrawn
- 1991-09-11 EP EP91917088A patent/EP0548234B1/en not_active Expired - Lifetime
- 1991-09-11 UA UA93004515A patent/UA48936C2/uk unknown
- 1991-09-11 SI SI9111508A patent/SI9111508B/sl unknown
- 1991-09-11 DK DK91917088T patent/DK0548234T3/da active
- 1991-09-11 MX MX9101042A patent/MX9101042A/es unknown
- 1991-09-11 YU YU150891A patent/YU49095B/sh unknown
- 1991-09-11 AT AT91917088T patent/ATE188739T1/de not_active IP Right Cessation
- 1991-09-11 DE DE69131903T patent/DE69131903T2/de not_active Expired - Lifetime
-
1994
- 1994-10-12 HR HR940668A patent/HRP940668B1/xx not_active IP Right Cessation
-
1995
- 1995-06-07 US US08/484,939 patent/US6319693B1/en not_active Expired - Fee Related
- 1995-06-07 US US08/480,020 patent/US5932476A/en not_active Expired - Fee Related
-
1997
- 1997-08-13 US US08/910,322 patent/US6238669B1/en not_active Expired - Fee Related
- 1997-08-13 US US08/910,618 patent/US5958424A/en not_active Expired - Fee Related
-
1999
- 1999-08-27 US US09/384,472 patent/US6509446B2/en not_active Expired - Fee Related
-
2000
- 2000-04-07 GR GR20000400866T patent/GR3033173T3/el not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06504195A (ja) | 鶏貧血症ウィルス(cav)組換え核酸、それを含むcav診断キット、および原核細胞または真核細胞、ならびにcav2本鎖dnaの製造方法 | |
KR0153005B1 (ko) | 제조합 마레크병 바이러스 | |
JPH02500409A (ja) | 弱毒化ヘルペスウイルス、アミノ酸配列コード化外来dna含有ヘルペスウイルス並びに同上含有ワクチン | |
JP3829290B2 (ja) | ニワトリ貧血症ウイルス変異体およびワクチン、ならびにウイルスタンパク質vp1、vp2およびvp3またはウイルスをコードする配列に基づくそれらのための用途 | |
US5047237A (en) | Attenuated pseudorabies virus having a deletion of at least a portion of a gene encoding an antigenic, nonessential protein, vaccine containing same and methods of identifying animals vaccinated with the vaccine | |
JPH05292976A (ja) | マレック病ウイルスワクチン | |
JPH07509122A (ja) | 野生型麻疹ウイルス糖タンパク質:ワクチンおよびその検出方法 | |
Liu et al. | Molecular characterisation of very virulent infectious bursal disease viruses in Taiwan | |
EP0513921B1 (en) | Recombinant vaccine against Marek's disease | |
KR0183368B1 (ko) | 페스트바이러스 뉴클레오티드 서열 및 폴리펩티드 | |
JP2905483B2 (ja) | 弱毒化ヘルペスウイルス及び外来性dnaを含むヘルペスウイルス | |
US20060073160A1 (en) | Cloning of chicken anemia virus DNA | |
US5106965A (en) | Detection of human adenovirus | |
US5693530A (en) | Marek's disease virus nucleotide sequence and methods of use | |
Hirasawa et al. | Differentiation of Wild‐and Vaccine‐type Canine Parvoviruses by PCR and Restriction‐enzyme Analysis | |
WO1991008310A1 (en) | Detection of human adenovirus | |
CA2185097A1 (en) | Activating virus | |
JPH04506747A (ja) | リサウィルス感染症の検出法および/または同定法、モコラリサウィルスのペプチドおよび/またはペプチドの断片をコードする遺伝子のクローン化と発現、モコラウィルスおよび/またはリサウィルス群に対するワクチン、および遺伝子工学による前記ワクチンの製造方法 | |
JPH06141853A (ja) | 組換え鶏伝染性喉頭気管炎ウイルス及びその製法 | |
Liu | Molecular genetic and biochemical studies of avian reovirus | |
REVIVALS | B5-ijgdae! | |
FR2601689A1 (fr) | Herpes virus attenues, herpes virus qui renferment de l'adn etranger codant pour une sequence d'amino-acides, et vaccins les contenant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071030 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081030 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081030 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091030 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101030 Year of fee payment: 12 |
|
LAPS | Cancellation because of no payment of annual fees |